Skip to main content
Premium Trial:

Request an Annual Quote

Aclara BioSciences, BD Biosciences


Aclara BioSciences has launched an expanded set of eTag gene-expression assays, which include 11 different pre-formatted and validated panels of genes that range in the number of genes monitored from six to 24. In addition to these gene panels, the company has assembled a collection of assays for other individual genes involved in drug toxicity that can be configured into multi-gene panels. In the ADME/Tox area, this collection comprises around 300 human genes and 100 rat genes.

BD Biosciences has launched its QZyme assays for quantitative PCR. The system, for the real-time detection and quantification of specific cDNA and genomic DNA targets, is compatible with all real-time PCR instruments for single or multiplex analyses, BD said. The assays, which can measure fewer than 10 copies of target DNA, require no optimization since they rely on a single set of PCR cycling parameters that can be universally applied to detect any genomic DNA or mRNA target.

Filed under

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.